Bibliography
- Campion D , DumanchinC, HannequinDet al.: Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum.Am. J. Hum. Genet.65(3), 664–670 (1999).
- Iqbal K , Grundke-IqbalI: Metabolic/signal transduction hypothesis of Alzheimer‘s disease and other tauopathies.Acta Neuropathol. (Berl.)109(1), 25–31 (2005).
- Braak H , BraakE, Grundke-IqbalIet al.: Occurrence of neuropil threads in the senile human brain and in Alzheimer‘s disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques.Neurosci. Lett.65(3), 351–355 (1986).
- Glenner GG , WongCW: Alzheimer‘s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.Biochem. Biophys. Res. Commun.120(3), 885–890 (1984).
- Grundke-Iqbal I , IqbalK, QuinlanMet al.: Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.J. Biol. Chem.261(13), 6084–6089 (1986).
- Grundke-Iqbal I , IqbalK, TungYCet al.: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.Proc. Natl Acad. Sci. USA83(13), 4913–4917 (1986).
- Mori H , KondoJ, IharaY: Ubiquitin is a component of paired helical filaments in Alzheimer‘s disease.Science235(4796), 1641–1644 (1987).
- Perry G , FriedmanR, ShawGet al.: Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.Proc. Natl Acad. Sci. USA84(9), 3033–3036 (1987).
- Wang GP , KhatoonS, IqbalKet al.: Brain ubiquitin is markedly elevated in Alzheimer disease.Brain Res.566(1–2), 146–151 (1991).
- McKhann G , DrachmanD, FolsteinMet al.: Clinical diagnosis of Alzheimer‘s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer‘s Disease.Neurology34(7), 939–944 (1984).
- Mizutani T , SakataM, SnookMEet al.: Pathological heterogeneity of Alzheimer type dementia.In: Alzheimer Disease: Biology, Diagnosis and Therapeutics. Wisniewski HM (Ed) John Wiley & Sons Ltd., Chichester, UK, 33, 247–255 (1997).
- Schott JM , PriceSL, FrostCet al.: Measuring atrophy in Alzheimer disease – a serial MRI study over 6 and 12 months.Neurology65, 119–124 (2005).
- Karas GB , ScheltensP, RomboutsSAet al.: Global and local gray matter loss in mild cognitive impairment and Alzheimer‘s disease.Neuroimage.23(2), 708–716 (2004).
- Best JD , JayMT, OtuFet al.: In vivo characterization of Aβ(40) changes in brain and cerebrospinal fluid using the novel γ-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) in the rat.J. Pharmacol. Exp. Ther.317(2), 786–790 (2006).
- El Mouedden M , VandermeerenM, Meert Tet al.: Reduction of Aβ levels in the Sprague Dawley rat after oral administration of the functional γ-secretase inhibitor, DAPT: a novel non-transgenic model for Aβ production inhibitors. Curr. Pharm. Des.12(6), 671–676 (2006).
- Fagan AM , MintunMA, MachRHet al.: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans. Ann. Neurol.59(3), 512–519 (2006).
- Clark CM , XieS, ChittamsJet al.: Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?Arch. Neurol.60(12), 1696–1702 (2003).
- Buerger K , EwersM, PirttilaTet al.: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.Brain129(Pt 11), 3035–3041(2006) (Epub ahead of print).
- Zemlan FP , RosenbergWS, LuebbePAet al.: Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins.J Neurochem.72(2), 741–750 (1999).
- Iqbal K , FloryM, KhatoonSet al.: Subgroups of Alzheimer‘s disease based on cerebrospinal fluid molecular markers.Ann. Neurol.58(5), 748–757 (2005).
- Anonymous: Consensus report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer‘s Disease‘. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging19(2), 109–116 (1998).
- Wang JZ , Grundke-IqbalI and Iqbal K: Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. (2006) (In press).
- Li L , SenguptaA, HaqueNet al.: Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.FEBS Lett.566(1–3), 261–269 (2004).
- Chohan MO , KhatoonS, IqbalIGet al.: Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine.FEBS Lett.580(16), 3973–3979 (2006).
- Gong CX , SinghTJ, Grundke-IqbalIet al.: Phosphoprotein phosphatase activities in Alzheimer disease brain.J. Neurochem.61(3), 921–927 (1993).
- Gunnarsson MD , KilanderL, SudelofJet al.: Reduction of hyperphosphorylated tau during memantine treatment of Alzheimer‘s disease. Alzheimer‘s & Dementia.2(3(S1)), S63–64 (2006).